Taysha Gene Therapies, Inc. TSHA Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$42.41M-52.3% | -$27.85M+14.9% | -$32.73M-21.8% | -$26.88M-24.9% | -$21.53M-14.6% | ||
| $295K-1.3% | $299K+49.5% | $200K-33.3% | $300K+6.0% | $283K-6.9% | ||
| $5.55M+57.2% | $3.53M+7.4% | $3.29M+3.0% | $3.19M-3.2% | $3.29M+2.4% | ||
| $1.29M+161% | -$2.13M-9.1% | -$1.95M-165% | $3M+225% | $923K+161% | ||
| $794K-62.8% | $2.14M+320% | -$971K— | —— | $1.05M+228% | ||
| -$27K+15.6% | -$32K-14.3% | -$28K+88.4% | -$241K-4,920% | $5K+107% | ||
| —— | -$5.49M— | $0+100% | -$1.99M+13.7% | -$2.3M-13.8% | ||
| $285K-28.7% | $400K+28.2% | $312K+1.3% | $308K-9.1% | $339K+12.6% | ||
| -$40.88M-53.0% | -$26.72M-10.6% | -$24.17M-19.7% | -$20.18M+8.3% | -$22.02M-20.3% | ||
| $24K-90.4% | $250K+131% | $108K+5,300% | $2K-99.5% | $378K— | ||
| —— | -$3K+95.0% | -$60K+6.3% | -$64K-814% | -$7K-155% | ||
| $3M— | —— | —— | —— | $378K— | ||
| -$3.02M-1,124% | -$247K-415% | -$48K— | —— | -$371K— | ||
| $516K-49.6% | $1.02M+739% | $122K— | $0-100% | $75K— | ||
| $19K+121% | -$90K+68.4% | -$285K-342% | $118K+248% | -$80K— | ||
| —— | —— | —— | —— | —— | ||
| $711K-98.6% | $49.56M+463% | $8.8M-95.9% | $216.29M+416,038% | -$52K— | ||
| -$43.19M-291% | $22.59M— | $0-100% | $196.17M+974% | -$22.44M-20.3% | ||
| $1.45M-0.2% | $1.45M+6.4% | $1.36M+5.5% | $1.29M-0.2% | $1.29M-0.6% | ||
| $295K-1.3% | $299K+49.5% | $200K-33.3% | $300K+6.0% | $283K-6.9% | ||
| -$5.15M-293% | $2.67M-46.6% | $5.01M+584% | $732K+134% | -$2.13M— | ||
| $794K-62.8% | $2.14M+320% | -$971K— | —— | $1.05M+228% | ||
| $32K-84.4% | $205K+10.2% | $186K+0.5% | $185K-27.7% | $256K+135% | ||
| $285K-28.7% | $400K+28.2% | $312K+1.3% | $308K-9.1% | $339K+12.6% | ||
| -$27K+15.6% | -$32K-14.3% | -$28K+88.4% | -$241K-4,920% | $5K+107% | ||
| —— | -$3K+95.0% | -$60K+6.3% | -$64K-814% | -$7K-155% | ||
| $3M— | —— | —— | —— | $378K— | ||
| —— | —— | —— | —— | $47K— | ||
| —— | $12.11M0.0% | $12.11M0.0% | $12.11M0.0% | $12.11M— | ||
| $19K+121% | -$90K+68.4% | -$285K-342% | $118K+248% | -$80K— | ||
| $176K— | —— | $84K— | —— | $75K— | ||
| —— | —— | —— | $388K+1,587% | $23K+100% | ||
| —— | $736K+152% | $292K+7.0% | $273K+368% | -$102K-22.9% | ||
| —— | -$5.49M— | $0+100% | -$1.99M+13.7% | -$2.3M-13.8% | ||
| —— | $56.25K0.0% | $56.25K0.0% | $56.25K0.0% | $56.25K— | ||
| —— | $593.5K0.0% | $593.5K0.0% | $593.5K0.0% | $593.5K— | ||
| —— | $409.25K0.0% | $409.25K0.0% | $409.25K0.0% | $409.25K— | ||
| -$40.9M-51.6% | -$26.97M-11.1% | -$24.27M-20.3% | -$20.18M+9.9% | -$22.4M-22.4% | ||
| -$40.9M-51.6% | -$26.97M-11.1% | -$24.27M-20.3% | -$20.18M+9.9% | -$22.4M-22.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Taysha Gene Therapies, Inc.'s cash flow data come from?
- Every line is extracted from Taysha Gene Therapies, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.